Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States.

Journal Article (Journal Article)

Objectives: To estimate years of potential life lost (YPLL) and present value of future lost productivity (PVFLP) associated with premature mortality due to HPV-attributable cancers, specifically those targeted by nonavalent HPV (9vHPV) vaccination, in the United States (US) before vaccine use. Methods: YPLL was estimated from the reported number of deaths in 2017 due to HPV-related cancers, the proportion attributable to 9vHPV-targeted types, and age- and sex-specific US life expectancy. PVFLP was estimated as the product of YPLL by age- and sex-specific probability of labor force participation, annual wage, value of non-market labor, and fringe benefits markup factor. Results: An estimated 7,085 HPV-attributable cancer deaths occurred in 2017 accounting for 154,954 YPLL, with 5,450 deaths (77%) and 121,226 YPLL (78%) attributable to 9vHPV-targeted types. The estimated PVFLP was $3.3 billion for cancer deaths attributable to 9vHPV-targeted types (86% from women). The highest productivity burden was associated with cervical cancer in women and anal and oropharyngeal cancers in men. Conclusions: HPV-attributable cancer deaths are associated with a substantial economic burden in the US, much of which could be vaccine preventable.

Full Text

Duke Authors

Cited Authors

  • Priyadarshini, M; Prabhu, VS; Snedecor, SJ; Corman, S; Kuter, BJ; Nwankwo, C; Chirovsky, D; Myers, E

Published Date

  • 2020

Published In

Volume / Issue

  • 8 /

Start / End Page

  • 624092 -

PubMed ID

  • 33665180

Pubmed Central ID

  • PMC7921151

Electronic International Standard Serial Number (EISSN)

  • 2296-2565

Digital Object Identifier (DOI)

  • 10.3389/fpubh.2020.624092

Language

  • eng

Conference Location

  • Switzerland